key: cord-0921042-os1cet5k
authors: Sinha, D; Mandal, C; Bhattacharya, DK
title: Identification of 9-O acetyl sialoglycoconjugates (9-OAcSGs) as biomarkers in childhood acute lymphoblastic leukemia using a lectin, Achatinin(H), as a probe
date: 1999-01-27
journal: Leukemia
DOI: 10.1038/sj.leu.2401239
sha: 0bb77918c07605bd1d2159a735ef779fab79faa6
doc_id: 921042
cord_uid: os1cet5k

Neoplastic transformation causes changes in cell surface architecture, most notably, aberrant sialylation. Exploiting the restricted specificity of a 9-O acetyl sialic acid (9-OAcSA) binding lectin, Achatinin(H) (ATN(H)), we have identified two 9-O acetyl sialoglyconjugates (9-OAcSGs) on lymphoblasts of 87 children suffering from acute lymphoblastic leukemia (ALL). The preferential binding of ATN(H) to lymphoblasts induces their 11-fold increased agglutination (81 ± 7.8%) compared to peripheral blood mononuclear cells (PBMC) of normal donors (8 ± 4.3%) which corroborates with flow cytometry studies. Agglutination of MOLT-4 (87 ± 4.8%), a lymphoblastoid cell line and MDCK (91.25 ± 0.01%), a cell line expressing surface 9-OAcSA, confirms the preferential binding of ATN(H) to lymphoblasts through their surface 9-OAcSGs. Furthermore, fluorometric quantitation reveals a 4.6-fold increase in % of 9-OAcSA on lymphoblasts of ALL patients (42.1 ± 4.1%) compared to normal donors (9.2. ± 3.4%). Western blotting confirms that ATN(H) recognizes two membrane sialoglycoconjugates, of MW 120 kDa and 90 kDa, both having 9-OAcSA α2 → 6 GalNAc terminal sugar moiety as their lectinogenic epitope. We propose that these 9-OAcSGs may serve as biomarkers for detection and monitoring of lymphoblasts in ALL and accordingly merit therapeutic considerations.

Neoplastic transformation is often associated with a variety of structural changes on the cell surface, most notably, changes in agglutinin receptor sites favoring cell agglutination by lectins 1,2 and increased sialic acid densities. 1 Sialic acids (SA), originally abbreviated as Neu5Ac, are a family of 9-carbon carboxylated monosaccharides often found as terminal residues of vertebrate oligosaccharides. 3 They are modified in various ways giving rise to a family of more than 30 different structures which in turn can be presented in a variety of linkages to the underlying sugar chains. 4, 5 These modifications significantly effect the physicochemical properties of parent molecule (Neu5Ac/SA) and can thereby modify and/or create new biological functions. 6, 7 In mammals, one of the most common modification of sialic acids is the addition of O-acetyl esters to hydroxyl groups at C 4 , C 7 , C 8 tions in the catabolism of glycoconjugates, 7 effects recognition of sialic acids by viral hemagglutinins and bacterial sialidases, 4,5 may effect tissue morphogenesis during development 8 and can modulate the alternative pathway of complement activation. 9 Lectins or lectin-like proteins endowed with the ability to bind sialoglycoconjugates have been used as recognition molecules to predict changes in the pattern of sialylation and the degree of O-acetylation during malignant transformation. [10] [11] [12] [13] Binding studies with Sambuccus nigra agglutinin (SNA) state de novo expression of specific sialic acids on selected glycoproteins in colon carcinoma. 14 Employing Ricinus cummunis agglutinin, the granulocytes of patients with chronic myelogenous leukemia (CML) are reported to contain more sialylated glycopeptides than normal granulocytes. 15, 16 Lymphoblasts of children with acute lymphoblastic leukemia (ALL) are also reported to be electrophoretically distinct from normal lymphocytes due to their increased concentration of sialic acids which causes charge differences. 17 A lectin, Cancer antennarius, which recognizes sialic acids O-acetylated both at C 4 and C 9 positions, has been used to identify an O-acetyl ganglioside, GD 3 , as a biomarker in human melanoma cells. 18 Although the major sialic acid in human is Neu5Ac, 9-O acetylated sialic acids (9-OAcSA) have been detected at a low level in human saliva, colonic mucins, serum and B lymphocytes 19 and are markedly elevated in melanomas 18 and ALL. 20, 21 However, the detailed biochemical characterization and biological significance of 9-OAcSA on lymphoblasts of ALL patients remains obscure.

Childhood ALL, a clonal lymphoproliferative disorder, is characterized by marked overproduction of lymphoblasts 22, 23 morphologically different from mature functional lymphocytes. 24 Analysis of cell surface structures specific to lymphoblasts of ALL patients may provide biomarkers useful for its diagnosis and prognosis. In a pilot study, exploiting the selective affinity of a lectin, Achatinin H (ATN H ) towards 9-OAcSA, 12,25-30 we have detected subtle changes on the surface of erythrocytes 20 and lymphocytes 21 in ALL patients. Employing ATN H as an analytical probe, the present study reports (1) the identification of specific biomarkers, ie 9-O acetyl sialoglycoconjugates (9-OAcSGs) on the surface of peripheral blood mononuclear cells (PBMC) of ALL patients by leukoagglutination, flow cytometry and Western blotting; (2) their quantitation; (3) determination of their molecular weight (MW); and (4) identifying their terminal oligosaccharide structure which serves as the binding epitope for ATN H .

Blood samples from 87 patients of clinically confirmed ALL, belonging to type L 1 or L 2 (FAB classification), 24 as per the light microscopical appearance of bone marrow smears, were taken. The patients were between 2.5-11 years age, of either sex and having a leukocyte count below 7 × 10 10 cells/l. Their salient presenting features were progressive pallor, anemia with occasional hemorrhagic spots, fever and bone pain.

Controls were normal healthy donors (n = 30) of either sex and different blood groups. Patients diagnosed for other hematological disorders (n = 26), ie CML (n = 7), non-Hodgkin's lymphoma (NHL, n = 4), acute myelogenous leukemia (AML, n = 5), thalassemia (n = 5) and aplastic anemia (n = 5) were also included in the study.

Peripheral blood (2-3 ml) was collected at Vivekananda Institute of Medical Science, Calcutta and coded samples sent to Indian Institute of Chemical Biology, Calcutta. The results were compared only on completion of assays to ensure 'blindness' in the protocol. Informed consent was taken from patients and the Human Ethical Clearance Committee as per the protocol of Indian Council of Medical Research.

A lymphoblastoid cell line, MOLT-4 (ATCC No. 1582), derived from an ALL patient and MDCK (ATCC No. CCL 34), a cell line expressing surface 9-OAcSA, 31 were included in the study.

The lectin, ATN H , with preferential affinity for sialoglycoconjugates having terminal 9-OAcSA in ␣2 → 6 linkage to the underlying structure, [25] [26] [27] [28] [29] [30] was purified from Achatina fulica snail. 12 Influenza C hemagglutinin esterase fusion protein (CHE-Fc) which recognizes sialoglycoconjugates with terminal 9-OAcSA, irrespective of their underlying structure, 32, 33 was a generous gift from Prof A Varki (Division of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA).

Di-isopropyl flurophosphate (DFP) was obtained from Aldrich (1 M) and stored in isopropyl alcohol at −20°C. All other chemicals and biological reagents were from Sigma (St Louis, MO, USA), unless otherwise stated. 34 PBMC were separated by Ficoll-Hypaque density centrifugation 35 and suspended in RPMI 1640, supplemented with 2 mM glutamine, gentamycin and 10% heat-inactivated human AB serum (medium A). PBMC (1 × 10 5 cells/100 l of medium A) of patients with ALL (n = 87), CML (n = 7), NHL (n = 4), AML (n = 5), thalassemia (n = 5) and aplastic anemia (n = 5) and normal donors (n = 30) were incubated with ATN H (2 g) for 1 h at 37°C. PBMC of patients with no ATN H served as cell control. The % of leukoagglutination was calculated as follows:

Leukoagglutination % in a field = Agglutinated cells Total cells × 100.

In parallel, to confirm the preferential binding of ATN H to leukemic blasts was through 9-OAcSA, agglutination of MOLT-4 and MDCK cell lines was also determined.

The % of 9-OAcSA on PBMC surface of ALL patients (n = 87)/normal donors (n = 30) and MOLT-4 and MDCK cell lines was determined as described by Shukla and Schauer. 36, 37 Briefly, PBMC (1 × 10 6 cells/100 l) were washed and suspended in buffer A (sodium chloride (3 g), potassium chloride (0.2 g), disodium hydrogen phosphate dihydrate (1 g), sodium dihydrogen phosphate monohydrate (0.15 g), potassium dihydrogen phosphate (0.2 g) per liter, pH 7.2). In one series, PBMC were hydrolyzed to saponify O-acetyl groups. In other series no de-O-acetylation was performed.

All samples were oxidized with sodium metaperiodate (200 l, 2.5 mM in buffer A) at 4°C for 15 min in the dark. After centrifuging at 12000 g for 5 min, supernatant (400 l) was mixed with sodium arsenite (100 l, 2% in 0.5 M HCl) and 300 l acetylacetone solution (0.075 M glacial acetic acid, 0.05 ml of acetylacetone and 3.75 g of ammonium acetate in 25 ml double-distilled water). After incubating at 60°C for 10 min samples (0.8 ml) were diluted to a final volume of 2.5 ml with double-distilled water. The relative fluorescence intensity ( max(exitation=410nm) , max(emmision=510nm) ) of each sample was measured against the reagent blanks. The % of 9-OAcSA was determined on a Hitachi F-4010 spectrofluorimeter (Hitachi, Tokyo, Japan) by subtracting the relative unsubstituted sialic acids from that obtained after de-0-acetylation.

ATN H was conjugated with fluorescein isothiocyanate (FITC) as described by Coligan et al. 38 Cells (1 × 10 6 cells/100 l) were suspended in medium A and their non-specific binding sites blocked for 30 min with 10% normal goat serum in the same medium. Following two washes, the cells were labelled with FITC-ATN H (2 g) at 0°C for 1 h. Cells labelled with FITC conjugated lipopolysaccharide (FITC-LPS), diluted to the same protein concentration as ATN H , served as a negative control. 39 The cells were washed, suspended in phosphate buffered saline (PBS, pH 7.2) and sorted using a FACS Calibur flow cytometer.

To determine the percentage of cells expressing common acute lymphoblastic leukemia antigen (CALLA), cells were incubated with anti-CALLA monoclonal antibody (mAb), of IgM class (2.5 g/50 l, Boehringer Mannheim, Mannheim, Germany), at 0°C for 1 h. A mouse IgM, diluted to the same protein concentration as anti-CALLA mAb, served as a negative control. Following three washes with medium A, the cells were labelled with 1:40 dilution of FITC-conjugated antimouse IgM at 0°C for 30 min. Cells were washed and sorted as previously described.

The binding of ATN H to surface 9-OAcSGs and not CALLA antigen was confirmed by flow cytometry studies employing two different fluorochromes for ATN H and anti-CALLA mAb. Initially, PBMC of ALL patients were incubated with anti-CALLA mAb (2.5 g/1 × 10 6 cells) for 1 h at 0°C. Following three washes in medium A, the binding of anti-CALLA mAb was detected by labeling the cells with 1:40 dilution of phycoerythrin (PE) conjugated goat anti-mouse IgM (Becton Dickinson, San José, CA, USA) for 30 min at 0°C. Subsequently, the 121 cells were incubated with FITC-ATN H (2 g) for 1 h at 0°C, washed and sorted, as previously described.

In parallel, PBMC incubated with mouse IgM (concentration matched with anti-CALLA mAb), followed by PE-conjugated goat anti-mouse IgM (1:40 dilution) and finally FITC-LPS (diluted to the same concentration as FITC-ATN H ) served as the corresponding negative control.

For lectin overlay experiments, PBMC membranes were prepared from ALL patients and normal donors according to Weissman et al. 40 The purity of membrane fractions was confirmed by measuring 5′ nucleotidase activity 41 and their protein concentration determined using bovine serum albumin (BSA) as the standard. 42 The membrane fractions (30 g) were reduced by boiling with ␤-mercaptoethanol for 10 min, electrophoresced on a 7.5% SDS-PAGE at 60 V for 1.5 h (Bio-Rad Minigel apparatus; Bio-Rad, Hercules, CA, USA) and transblotted on a nitrocellulose paper at 100 V for 2 h. The membranes were blocked overnight at 4°C in Tris-buffered saline (0.05 M TBS, pH 7.4), containing 10% desialylated BSA (ds-BSA) and probed with 125 I-ATN H (10 6 c.p.m./ml in TBS-dsBSA containing 0.03 M calcium chloride) for 1 h at 25°C. After extensive washing with TBS having 0.2% noniodate 40 (NP40) and 0.2% Tween 20, the paper was dried and loaded on to X-ray film for autoradiography. For de-O-acetylation of membrane fractions, the blots were incubated with 0.1 N sodium hydroxide (NaOH) for 45 min at 4°C, neutralized by extensive washing with TBS and similarly processed.

Membrane sialoglycoproteins with terminal 9-OAcSA were also detected using CHE-Fc as a probe. CHE-Fc is a soluble and versatile chimeric protein that retains both the hemagglutinin and esterase activity of influenza C virus as well as those of the Fc portion of human IgG 1 . 5,31-33 At ambient temperature and neutral pH, the esterase activity is dominant and it cleaves of the 9-O-acetyl groups of sialic acid. The use of CHE-FcD as a probe to detect sialoglycoconjugates having terminal 9-OAcSA has been validated by several groups. 5,31-33 CHE-Fc (10 g/ml) was treated with 1 mM DFP to irreversibly block the esterase activity and stabilize the hemagglutinin activity to give a probe (CHE-FcD) that specifically detects sialoglycoproteins with terminal 9-OAcSA at ambient temperature. 33 Sialoglycoproteins reacting with CHE-FcD were colorimetrically detected with goat anti-human IgG antibody-conjugated horse-radish peroxidase.

Hemagglutination inhibition assays using mono-, di-and trisaccharides containing 9-OAcSA and various sialoglycoproteins, mainly bovine submaxillary mucin (BSM) having 20% 9-OAcSA, have confirmed that ATN H selectively binds to sialoglycoconjugates having terminal 9-OAcSA in ␣2 → 6 linkage to a subterminal GalNAc of the underlying structure (Table 1) . Sialoglycoproteins, ie sheep submaxillary mucin (SSM), having only sialic acid, is 350-fold less inhibitory to ATN H in comparison to BSM. 25, [28] [29] [30] The preferential affinity of this lectin towards 9-OAcSA (K a = 1.20 × 10 3 ± 0.07 × 10 3 M −1 ) as compared to other O-acetylated derivatives has been confirmed by physicochemical techniques. 26, 27 ATN H preferentially binds to and agglutinates leukemic blasts PBMC of ALL patients showed an 11-fold increased agglutination (81 ± 7.8%), in response to ATN H (Table 2) , as compared to normal donors (8 ± 4.3%). No inherent leukoagglutination was observed for ALL patients in the absence of ATN H . The patients of other hematological disorders showed a distinctly low, ie NHL (2.35 ± 0.4) thalassemia (2.82 ± 0.8) or no leukoagglutination, ie CML, AML and aplastic anemia, in response to ATN H . The observation that ATN H agglutinates the cells through binding to surface 9-OAcSA is evident from a 91.25 ± 0.01% agglutination of MDCK cell line. An 87 ± 4.8% agglutination of MOLT-4 cell line reflects the preferential binding of ATN H to leukemic blasts. Furthermore, the pattern Table 2 Leukoagglutination in response to ATN H of agglutination is different in that the total number of cells per clump is distinctly higher in ALL patients and MOLT-4 and MDCK cell lines, as compared to normal donors, where clumps of maximum two or three cells are observed.

The increase in % of 9-OAcSA on PBMC surface of ALL patients, MOLT-4 and MDCK cell lines in comparison to normal donors was confirmed by its fluorimetric quantitation ( Figure 1 ). The mean (X ± s.d.%) of % 9-OAcSA in ALL patients was 4.6 folds higher (42.1 ± 4.1%) than normal donors (9.2 ± 3.4%). The % 9-OAcSA of 49.2 ± 0.01% for MOLT-4 and 71.6 ± 0.01% for MDCK cell lines reasons for their higher agglutination in the presence of ATN H . Figure 3 gives a representative profile of double-color flow cytometry studies to identify both CALLA antigen and 9-OAcSGs on leukemic blasts of an ALL patient. Of the total cell population, 78.27% were CALLA + 9-OAcSGs + in comparison to a very low percentage of CALLA + 9-OAcSGs − (1.02%) and CALLA − 9-OAcSGs + cells (2.20%, Figure 3a ). The data therefore reflect the binding of both ATN H and anti-CALLA mAb to leukemic blasts but through two different receptors, namely, 9-OAcSGs and CALLA antigen. In parallel, PBMC incubated with concentration matched mouse IgM and FITC-LPS, served as the corresponding negative control (Figure 3b ).

A representative profile of PBMC membrane glycoproteins, both from ALL patients (lane 1) and normal donors (lane 2) as observed by periodic acid Schiff's base staining is shown in Figure 4a . Amongst the membrane glycoproteins, sialoglycoproteins with terminal 9-OAcSA (9-OAcSGs) were directly detected by immunoblotting employing CHE-FcD as a probe (Figure 4b) . Blots of PBMC membrane proteins showed selective expression of 9-OAcSA on specific membrane glycoproteins of MW 120 kDa, 101 kDa, 90 kDa, 34 kDa, 36 kDa, 31 kDa and 25 kDa in ALL patient (Figure 4b , lane 1, Table 3 ) as compared to 40 kDa, 36 kDa and 29 kDa in normal donors (Figure 4b , lane 2, Table 3 ). The staining was completely abol- ished after alkali treatment (data not shown) owing to de-Oacetylation of 9-OAcSGs.

Of the 9-OAcSGs being recognized by CHE-FcD, only two sialoglycoproteins of MW 120 kDa and 90 kDa, in ALL patients (Figure 4c, lane 1) , showed strong reactivity with 125 -I-ATN H in addition to a 9-OAcSG (MW 36 kDa), common to ALL patients and normal donors (Figure 4c , lane 2, Table 3 ). After de-O-acetylation, these bands disappeared (data not shown) confirming that they are O-acetylated sialoglycoproteins presumably containing terminal 9-OAcSA␣2 → 6GalNAc which serves as the binding epitope for ATN H .

Interest in the use of biomarkers to evaluate future disease risk has increased greatly in recent years since they are observable end-points in a continuum of events leading from exposure to toxic agents to diseases that ultimately result from exposure. Employing the observation that cytokines in general induce tyrosine phosphorylation in lymphoid progenitor cells and constitutive tyrosine phosphorylation is also observed in Blineage ALL, attempts have been made to block the growth of leukemic blasts by using blockers against protein tyrosine kinases. 43 Alteration in the pattern of DNA methylation have been recently reported as a biomarker in various neoplasms, including ALL. 44 Changes in the sialylation pattern of cell surface structures during malignancies are also reported. 1, [10] [11] [12] [13] [14] 17, 18 The present study identifies two biomarkers, 9-OAcSGs, appearing exclusively on leukemic blasts of ALL patients employing ATN H as an analytical probe. ATN H selectively binds to leukemic blasts (Figure 2a ) inducing their 11-fold increased agglutination as compared to PBMC of normal donors (Table 2 ). Since ATN H is a 9-OAcSA binding lectin (Table 1) , leukoagglutination and flow cytometry studies indirectly reflect either (1) an increase in % of leukemic blasts, expressing 9-OAcSGs; and/or (2) an increased 9-O-acetylation of surface sialoglycoconjugates on leukemic blasts. These results are further supported by fluorimetric quantitation of surface 9-OAcSA which shows a 4.6-fold increase in ALL patients as compared to normal donors ( Figure 1 ). This observation is consistent with the previous reports which state that although 9-OAcSA are present at a very low concentration in normal human serum and B lymphocytes 19 their level is markedly elevated in melanomas 18 and ALL. 20, 21 The preferential binding of ATN H to leukemic blasts through 9-OAcSGs is further envisaged by an 87% and 91% agglutination of MOLT-4 and MDCK cell lines (Table 2) , both showing a five-and eight-fold increase in the % of surface 9-OAcSA compared to normal donors ( Figure 1 ).

Flow cytometry studies of a representative ALL sample state that the % of FITC-ATN H positive cells (93.81%, Figure 2a ) are comparable to the cells expressing CALLA antigen (92%, Figure 2a ) as also are the % of leukemic blasts (90%) as per morphological estimates. Comparison of these three observations reiterates the selective binding of ATN H to leukemic blasts of ALL patients having an increased surface 9-OAcSGs ( Figure 1 ). Furthermore, double-color flow cytometry studies, employing different fluorochromes for ATN H and anti-CALLA mAb ( Figure 3 ) reflect that they recognize two different receptors, ie 9-OAcSGs and CALLA antigen, on the surface of leukemic blasts. It is of interest that ATN H binds to leukemic blasts of patient with B cell ALL (Figure 2a, panel 2B) and also MOLT-4 ( Figure 2a, panel 3B) , a T lymphoblastoid cell line. Therefore, possibly the 9-OAcSGs, are common markers expressed on leukemic blasts of ALL patients irrespective of their B/T lineage. Furthermore, the study extended to patients of other hematological disorders demonstrates no cross-reactivity (Table 2) reiterating that 9-OAcSGs recognized by ATN H are present exclusively on leukemic blasts of ALL patients.

Western blotting of membrane proteins with 125 I-ATN H confirms the presence of two unique surface 9-OAcSGs (MW 120 kDa and 90 kDa) exclusively present in ALL patients (Figure 4c , Table 3 ). After de-O-acetylation, these bands disappear indicating that these are O-acetylated sialoglycoproteins. However, in addition many other bands appear on immunoblotting with CHE-FcD (Figure 4b , Table 3 ). This can be explained by the previous report which states that unlike ATN H which binds to sialoglycoconjugates with terminal 9-OAcSA in ␣2 → 6 linkage to a subterminal sugar, GalNAc, 25-30 the CHE-FcD binds to any sialoglycoconjugate having terminal 9-OAcSA irrespective of underlying structure. [31] [32] [33] Possibly, other 9-OAcSGs reacting with CHE-FcD but not 125 I-ATN H represent either (1) sialoglycoproteins with terminal 9-OAcSA linked to the underlying structure by a linkage different from ␣2 → 6, or (2) their binding epitopes are not in proper conformation required for recognition by ATN H . Therefore, both 120 kDa and 90 kDa 9-OAcSGs, in ALL patients, binding to 125 -I-ATN H and CHE-FcD are O-acetylated glycoproteins containing a terminal 9-OAcSA. Consider-ing the binding specificity of ATN H (Table 1) , we infer that the lectinogenic epitope of these 9-OAcSGs is presumably 9-OAcSA ␣2 → 6 GalNAc.

The relationship between 9-O-acetylation of sialic acids during neoplastic transformation and abnormalities seen in the immune system remains poorly defined. However, 9-O-acetylation has been reported to abrogate the normal functions of sialic acids in preventing the activation of alternative complement pathway due to involvement of the exocyclic side chain of sialic acid. 45 We have reported earlier that the exocyclic side chains of sialic acid molecules are also important determinants for ATN H binding. 25, [27] [28] [29] Certain viruses, ie influenza and corona viruses have been reported to specifically bind to 9-OAcSAs to mediate their effects. 5, [31] [32] [33] In contrast, removal of 9-OAcSAs has been reported to enhance the binding and invasion of malarial parasites in murine erythrocytes. 46 Sjoberg et al 47 have reported that 9-O-acetylation of sialic acids in melanomas can mask the binding site of adhesion molecules like CD22␤ which recognizes ␣ 2 → 6 linkages similar to lectinogenic epitope of ATN H . 25, 28, 29 This observation is further corroborated as increased binding of CD22␤ occurs following removal of 9-O-acetylated moiety by a specific enzyme, 9-O-acetyl esterase. We envisage that increased expression of 9-OAcSGs could mask binding sites of adhesion molecule(s) like CD22␤, thereby influencing cell adhesiondependent cellular responses namely cell proliferation and differentiation, immune responses and metastases. Based on these observations, it is reasonable to hypothesize that the increased 9-O-acetylation in ALL could modify host defense functions which may serve as an effective strategy of leukemic blasts to circumvent immune surveillance.

To the best of our knowledge, this is the first report which identifies and partially characterizes two surface 9-OAcSGs as biomarkers in ALL patients. The newly identified biomarkers may help in the development of new therapeutic strategies in the field of ALL research. Studies on the variable expression of these 9-OAcSGs in ALL patients under different phases of treatment have also been recently communicated. 48 

Increased sialic acid density in surface glycoproteins of transformed and malignant cells -a general phenomena?

Agglutination of granulocytes from chronic myeloid leukemia by concanavalin A

Chemistry, metabolism and biological functions of sialic acids

Biosynthesis and function of N and O substituted sialic acids

Diversity in the sialic acids

Sialic acid 9-O-acetylation on murine erythroleukemia cells affects complement activation, binding to I-type lectins and tissue homing

Neuraminidase-resistant sialic acid residues of gangliosides

Developmental abnormalities in transgenic mice expressing a sialic acidspecific 9-O-acetylesterase

An autosomal dominant gene regulates the extent of 9-O-acetylation of murine erythrocyte sialic acids: a probable explanation for the variation in capacity to activate the alternative complement pathway

The lectin from the crustacean Liocarcinus depurator recognizes O-acetyl sialic acids

Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages

A single step purification of a sialic acid binding lectin (Achatinin H ) from Achatina fulica snail

A monoclonal antibody recognizes an O-acetylated sialic acid in a human melanoma-associated ganglioside

Colon carcinoma glycoproteins carrying ␣-2,6-linked sialic acid reactive with Sambucus nigra agglutinin are not constitutively expressed in normal human colon mucosa and are distinct from sialyl-Tn antigen

Structures of sialylated fucosyl polylactose aminoglycans isolated from chronic myelogenous leukemia cells

Structures of O-linked oligosaccharides isolated from normal granulocytes, chronic myelogenous leukemia cells and acute myelogenous leukemia cells

Electrophoretic mobility distributions of normal hu man T and B lymphoblasts and of peripheral blood lymphoblasts in acute lymphocytic leukemia: effects of neuraminidase and of solvent ionic strength

Human melanoma antigen O-acetylated ganglioside GD3 is recognized by cancer antennarius lectin

The nature of sialic acids in human lymphocytes

O-acetylated sialic acid as a distinct marker for differentiation between several leukemia erythrocytes

O-acetyl sialic acid binding lectin, as a probe for detection of subtle changes on the cell surface induced during acute lymphoblastic leukemia (ALL) and its clinical application

Leukemia and the disruption of normal hematopoiesis

Acute lymphoblastic leukemia

Analysis of the presenting features of adult acute leukemias: the French-American-British classification

Characterization of cell surface sialoglycoconjucates using a unique lectin Achatinin H

Chemical modification studies of a unique sialic acid binding lectin from the snail Achatina fulica

Physicochemical studies on Achatinin H , a novel sialic acid binding lectin

The specificity of the binding site of Achatinin H , a sialic-acid binding lectin from Achatina fulica snail

A unique specificity of a sialic acid binding lectin Achatinin H from the hemolymph of Achatina fulica snail

Sialic acid binding lectins

Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line

9-O-acetylated sialic acids have widespread but selective expression: analysis using a chimeric dual function probe derived from influenza C hemagglutinin esterase

Influenza C virus uses 9-O-acetyl-N-acetyl neuraminic acid as a high affinity receptor determinant for attachment to cells

Leukoagglutination in patients with Hemophilia

Isolation of mononuclear cells and granulocytes from human blood

Fluorometric determination of unsubstituted and 9(8)-O-acetylated sialic acids in erythrocyte membranes

Analysis of sialic acids

Current Protocols in Immunology. National Institute of Health

Molecular cloning of zeta chain of the T cell antigen receptor

Isolation of golgi apparatus

Protein measurement with the folin phenol reagent

Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor

Van den Heuvel LP. DNA methylation patterns in the calcitonin gene region at first diagnosis and at relapse of acute lymphoblastic leukemia (ALL)

Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H

Binding of Plasmodium falciparum 175 kilodalton erythrocyte binding antigen and invasion of erythrocyte requires N-acetyl-neuraminic acid but not its O-acetylated form

Natural ligands of B cells adhesion molecule CD 22␤ can be masked by 9-O-acetylation of sialic acids

Development of a simple, blood based lymphoproliferation assay to determine treatment outcome and predict relapse in childhood acute lymphoblastic leukemia employing a 9-O-acetyl sialic acid binding lectin, ATN H , as a probe

The work was funded by the Department of Science and Technology, Government of India. DS is a senior research fellow of Council of Scientific and Industrial Research, New Delhi, Government of India. We thank Dr S Banerjee for his help in flow cytometry studies and Dr M Chatterjee (Indian Institute of Chemical Biology, Calcutta) for expediting the manuscript. Prof. R Schauer (Kiel University, Germany) is also acknowledged for editing the manuscript. Prof A Varki (Division of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093) is acknowledged for his generous gift of influenza C hemagglutinin esterase fusion protein (CHE-Fc).